Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer

NCT02893917 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02893917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02893917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 11, 2017
Completion date
May 31, 2027
Enrollment
90 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

advanced prostate adenocarcinoma with neuroendocrine differentiation, castration-resistant prostate carcinoma, metastatic prostate adenocarcinoma with neuroendocrine differentiation, metastatic prostate carcinoma, prostate adenocarcinoma with neuroendocrine differentiation, stage iv prostate adenocarcinoma ajcc v7